Namaxir (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a cofactor needed for DNA, RNA and protein synthesis. By limiting nucleotide formation, it suppresses the proliferation of immune cells and malignant cells, providing anti‑inflammatory and anti‑cancer effects.

The dose of Namaxir is individualized and set by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. Healthcare providers determine the appropriate amount and schedule for each patient.

Methotrexate is classified as Pregnancy Category X because it is teratogenic and can cause fetal harm. It is contraindicated during pregnancy and should be stopped well before conception. Use while breastfeeding is not recommended, as the drug can be excreted in milk and affect the infant.

To order Namaxir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Compared with biologic DMARDs such as adalimumab, methotrexate (Namaxir) is an oral or injectable small‑molecule agent that is less expensive and has a well‑established safety profile, but it may be slower to achieve disease control. Unlike newer biologics, it does not target specific cytokines, so it is often used in combination with other agents for optimal effect.

Namaxir should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures. Do not freeze. Follow standard aseptic handling procedures when preparing for injection.

Namaxir is supplied as a sterile solution for parenteral use and is administered by a qualified healthcare professional via epidural, intra‑articular or intramuscular injection, depending on the therapeutic indication and the prescribing protocol.

The most serious risks include severe liver toxicity, pulmonary fibrosis or interstitial pneumonitis, profound bone‑marrow suppression leading to anemia or infection, and acute renal failure. Patients should be monitored regularly for signs of these complications, and therapy should be discontinued if they occur.

Namaxir is contraindicated in pregnant women, individuals with severe hepatic disease, significant renal impairment, active uncontrolled infections, and patients with known hypersensitivity to methotrexate or any component of the formulation. Caution is also advised for patients with pre‑existing blood‑cell disorders.